This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
When you hear the words “healthcare privateequity,” two thoughts probably come to mind: Wait a minute, isn’t healthcare a risky/growth-oriented sector? In most of the world, healthcare is either government-run or a mixed public/private sector. Are there many private healthcare companies for PE firms to acquire?
For top privateequity firms, there’s a lot to like about SaaS. Top Software PrivateEquity Firms Here is a select list of the most active PE investors in the SaaS and software industry over the past year (data taken from the SEG 2024 Annual SaaS Report ). The firm employs 93 professionals.
continues their goal of acquiring and integrating leading medical aesthetics clinics, enabling medical professionals in their subsidiaries to achieve personal and professional goals while creating world-class customer experiences by networking support, collaboration, and community.
Summary Privateequity-backed Physician Practice Management (“PPM”) companies in the ENT & Allergy space continued a conservative growth trajectory during Q1 2024. Introduction Privateequity groups began investing in the ear, nose, and throat and allergy space in 2018.
Serving a variety of end markets, including aerospace & defense, electronics and industrials, National offers especially deep experience in the medical end market across various implantable devices, including pacemakers, neuromodulation devices, defibrillators, batteries and capacitors. National”).
But some subsectors, such as beauty, fragrance, residential services and medical spas, remained active as risk-off investors shifted deal activity toward categories they view as less discretionary, according to Leonhardt. portfolio company Birkenstock GmbH & Co. KG having an underwhelming start.
Targeting sectors with rigorous technical specifications, regulatory compliance standards, and exacting quality requirements, MSK serves customers primarily in the medical, aerospace & defense and telecommunications end markets.
Excolere Equity Partners is a leading middle market privateequity firm that leverages its deep sector experience and strategic and operational expertise to accelerate the growth and enhance the impact of companies in the Education and Human Capital sector. ISP Schools is a portfolio company of OMERS PrivateEquity.
CORE, a privateequity firm focused on manufacturing, industrial technology, and industrial services, previously acquired GEM, a provider of precision deep-drawn metal components and mechanical assemblies, in February 2023. PMP”), a provider of specialty stamping and machining services. FOCUS represented CORE in this transaction.
The fund will not invest in hardware, medical devices or consumer social networks. The Notion portfolio includes Dixa, GoCardless, Mews, Paddle, Unbabel and Yulife. Wayra UK Telefónica’s innovation arm with more than 550 active portfolio companies, 35% of which are working with Telefónica.
Summary Privateequity’s investments in ophthalmology are entering a new, more mature lifecycle phase. We also expect many platform recapitalizations once privateequity groups and lenders become comfortable with the interest rate environment. A third group (e.g., We also see them being aggressive about acquisitions.
As the Federal Reserve moves toward a more predictable and potentially lower rate trajectory, financing conditions are expected to improve, enabling both strategic buyers and privateequity investors to pursue transactions with greater confidence.
He had made some good friends and close colleagues in the field and had seen how they raised funds to buy a small portfolio of businesses. The brand also receives many medical referrals from podiatrists and other foot specialists. John Prothrow had a background in mergers and acquisitions and had worked on the buy side of transactions.
Number of investments a year: Approx 10 Examples of previous investments: White Label Loyalty, Previsico, The Bunch, Beaconsoft and LightPoint Medical. Number of investments a year: 15 Examples of previous investments: Chargemaster, Ebury, Pod, PayasUgym, PowerX and Lightpoint Medical. Contact: john@advantagebusinessangels.co.uk
Complex and novel transaction structures for the sector also were a prominent result of the market and regulatory environment, with reverse mergers remaining a fixture and stock-for-stock deals and take-private transactions led by privateequity sponsors entering the scene.
approved prescription cannabidiol medicine to its portfolio. In November, Johnson & Johnson announced that it will split itself into two publicly traded companies , separating its pharmaceutical and medical devices businesses from its consumer products business. driven assets. 19 fueled revenue aside, cash is still king.
Out of the Nordic countries, companies such as Novo Nordisk capitalized on massive revenue boosts from weight-loss medications (Wegovy and Ozempic) with multibillion-dollar acquisitions. As a result, we expect PE activity to be particularly robust throughout the year, driving cross-border dealmaking in the process.
However, deal activity fizzled in the second half of 2022, as high inflation, aggressive anti-inflation monetary policies, geopolitical instability, assertive antitrust regulators and tightening financing markets depressed target valuations, reduced strategic acquirer confidence and sidelined privateequity sponsor buyers. trillion. [2]
McKessons acquisition of PRISM Vision Group is an important milestone for privateequitys investments in optometry practices. At the same time, there has always been uncertainty about the ultimate home for these assets, since privateequity does not keep its investments forever.
2) Portfolio Concentration The average biotech hedge fund has a concentrated portfolio because it takes significant time and resources to monitor each position. It operates venture capital, privateequity, and private credit funds and even does strategic partnerships with universities and institutes. or Ph.D.),
We organize all of the trending information in your field so you don't have to. Join 38,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content